CN
Search Within
SML0881
Applied Filters:
Keyword:'SML0881'
Showing 1-30 of 34 results for "SML0881" within Papers
Galeno Rojas et al.
Medicina, 73(3), 213-223 (2013-06-05)
Cognitive impairment and dementia treatment costs are significant for health systems. According to national and international guidelines, recommended drugs for treatment of dementias are cholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine. Despite these guidelines recommendations, other nootropics, vasodilators and antioxidants
Katherine L Possin et al.
Movement disorders : official journal of the Movement Disorder Society, 28(10), 1384-1390 (2013-07-13)
The objective of this study was to investigate how acetylcholinesterase inhibitor (ChEI) treatment affects brain function in Parkinson's disease (PD). Twelve patients with PD and either dementia or mild cognitive impairment underwent task-free functional magnetic resonance imaging before and after
Jacqueline Birks et al.
The Cochrane database of systematic reviews, 5(5), CD004744-CD004744 (2013-06-04)
Vascular dementia represents the second most common type of dementia after Alzheimer's disease. In older patients, in particular, the combination of vascular dementia and Alzheimer's disease is common, and is referred to as mixed dementia. The classification of vascular dementia
Kevin R Peters
Journal of the American Geriatrics Society, 61(7), 1170-1174 (2013-05-29)
To highlight the utility of using an effect size analysis to communicate the effectiveness of treatment interventions. Secondary analysis. Previously published systematic review on cholinesterase inhibitors (ChEIs) in Alzheimer's disease. Individuals with mild to moderate Alzheimer's disease. Six-month randomized controlled
Hideyuki Hattori
Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 115(1), 22-31 (2013-05-23)
Galantamine, rivastigmine, and memantine, for the treatment of Alzheimer-type dementia, became covered by national health insurance last year in Japan. Galantamine and rivastigmine are choline esterase inhibitors, and memantine is a glutamate NMDA receptor antagonist. Galantamine also acts on the
Nastaran Majdi Nasab et al.
JPMA. The Journal of the Pakistan Medical Association, 62(7), 677-680 (2013-07-23)
To assess the efficacy of the Ginkgo biloba in patients with dementia of the Alzheimer type in slowing down the disease's degenerative progression and the patients' cognitive impairment compared with rivastigmine. Total 56 patients aged 50-75 years, suffering from dementia
Carina Wattmo et al.
Clinical interventions in aging, 8, 329-339 (2013-05-18)
To investigate the long-term effects of cholinesterase inhibitor (ChEI) therapy and the influence of sociodemographic and clinical factors on the use of community-based home help services (HHS) by patients with Alzheimer's disease (AD). This 3-year, prospective, multicenter study included 880
Martin R Farlow et al.
CNS neuroscience & therapeutics, 19(10), 745-752 (2013-08-09)
The 24-week, prospective, randomized, double-blind ACTION study investigated the efficacy, safety, and tolerability of 13.3 versus 4.6 mg/24 h rivastigmine patch in patients with severe Alzheimer's disease (AD). Patients had probable AD and Mini-Mental State Examination scores ≥3-≤12. Primary outcome
Agadi Hiremath Thippeswamy et al.
Journal of acupuncture and meridian studies, 6(4), 208-213 (2013-08-27)
The objective of this study was to evaluate the synergistic activity of Bacopa monniera with Rivastigmine against aluminum-chloride (AlCl3)-induced cognitive impairment in rats. Adult male Wistar rats were divided into ten groups (n = 10) and subjected to their assigned
Emily J Henderson et al.
BMC neurology, 13, 188-188 (2013-12-05)
Gait impairment is common in people with Parkinson's disease. There is a lack of effective interventions to target this debilitating complication and therefore a need to identify new therapeutic options. An underlying cholinergic deficit contributes to both the gait and
Magdalena Paczkowska-Walendowska et al.
Pharmaceutics, 13(11) (2021-11-28)
Polygoni cuspidati root is a resveratrol-rich source with anti-inflammatory, angiogenic and neuroprotective effects. The raw material was standardized for the content of resveratrol, for which there is a special justification for administration within the oral mucosa. To improve the solubility
A Servello et al.
Minerva medica, 105(2), 167-174 (2014-04-15)
Vascular dementia (VaD) is defined as a loss of cognitive function resulting from ischemic, hypoperfusive, or hemorrhagic brain lesions due to cerebrovascular disease or cardiovascular pathology. The main types of VaD are: Small Vessel Disease Dementia (sVAD), Large vessel disease
David Devos et al.
Journal of neurology, neurosurgery, and psychiatry, 85(6), 668-674 (2013-11-13)
Even with optimal dopaminergic treatments, many patients with Parkinson's disease (PD) are frequently incapacitated by apathy prior to the development of dementia. We sought to establish whether rivastigmine's ability to inhibit acetyl- and butyrylcholinesterases could relieve the symptoms of apathy
[Exacerbation of psoriasiform lesions by a gamma-secretase inhibitor].
P Trechot et al.
Annales de dermatologie et de venereologie, 140(10), 669-670 (2013-10-05)
Kalpana Nagpal et al.
International journal of biological macromolecules, 59, 72-83 (2013-04-20)
The study aims at formulation and optimization brain targeted nanoparticles (NP) of Rivastigmine (RT) to improve its therapeutic potential and to verify its safety profile. The NP were optimized using a two factor three level (3(2)) central composite design aiming
Jerrold B Leikin et al.
The American journal of emergency medicine, 32(7), 815-815 (2014-03-05)
Although cholinesterase inhibitors have been frequently used in the treatment of Alzheimer disease, its effects on serum cholinesterase concentrations have been rarely described. We described significant depression of serum cholinesterase levels due to cholinesterase inhibitor toxicity from redundant use of
Dian He et al.
The Cochrane database of systematic reviews, 12(12), CD008876-CD008876 (2013-12-18)
This is an update of the Cochrane review "Pharmacologic treatment for memory disorder in multiple sclerosis" (first published in The Cochrane Library 2011, Issue 10).Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, demyelinating, neurodegenerative disorder of the central nervous system
Tarek Mohamed et al.
European journal of medicinal chemistry, 126, 823-843 (2016-12-13)
A library of fifty-seven 2,4-disubstituted quinazoline derivatives were designed, synthesized and evaluated as a novel class of multi-targeting agents to treat Alzheimer's disease (AD). The biological assay results demonstrate the ability of several quinazoline derivatives to inhibit both acetyl and
Atrial flutter in a patient with Alzheimer dementia treated by rivastigmine.
Yi-Chien Hsu et al.
The Journal of neuropsychiatry and clinical neurosciences, 25(2), E25-E26 (2013-05-21)
Monica Passananti et al.
Water research, 47(14), 5422-5430 (2013-07-19)
In this paper we investigated the degradation of the rivastigmine drug induced by hydroxyl radical in synthetic and natural waters focusing on both reactivity and photoproducts identification. The hydroxyl radical formation rate was quantified by using terephthalic acid as trapping
Serge Gauthier et al.
Current medical research and opinion, 29(8), 989-1000 (2013-05-08)
To assess the real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease (AD) in Canada. Eighteen-month observational, prospective, multi-center, open-label study conducted on AD patients with Standardized Mini-Mental State Examination (SMMSE) score of 10-26
Steven H Ferris et al.
Clinical interventions in aging, 8, 1007-1014 (2013-08-16)
Alzheimer's disease is characterized by progressively worsening deficits in several cognitive domains, including language. Language impairment in Alzheimer's disease primarily occurs because of decline in semantic and pragmatic levels of language processing. Given the centrality of language to cognitive function
Shigeki Moriguchi et al.
Journal of neurochemistry, 128(6), 927-937 (2013-10-30)
Because the cholinergic system is down-regulated in the brain of Alzheimer's disease patients, cognitive deficits in Alzheimer's disease patients are significantly improved by rivastigmine treatment. To address the mechanism underlying rivastigmine-induced memory improvements, we chronically treated olfactory bulbectomized (OBX) mice
Desk Reference of Clinical Pharmacology, Second Edition, 824-824 (2007)
George Grossberg et al.
American journal of Alzheimer's disease and other dementias, 28(6), 583-591 (2013-08-29)
Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer's disease (AD). Post hoc analysis of OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA), a double-blind trial comparing 13.3 and 9.5 mg/24
Magdalena Paczkowska-Walendowska et al.
Antioxidants (Basel, Switzerland), 10(12) (2021-12-25)
Blackberry fruits are recognized as functional foods while blackberry leaves are outside this classification and they also contain active compounds with health-promoting potential. Therefore, the aim of this study was the phytochemical analysis of blackberry leaves of varieties (Chester, Loch
Keith Wesnes
Drugs of today (Barcelona, Spain : 1998), 43(6), 349-359 (2007-07-07)
Parkinson's disease is associated with dementia in about 40% of cases, and in time up to 80% of patients will develop dementia. This dementia is characterized by deficits in attention, executive function and memory. While, as in Alzheimer's disease, cholinergic
Andrea C Tricco et al.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 185(16), 1393-1401 (2013-09-18)
Cognitive enhancers, including cholinesterase inhibitors and memantine, are used to treat dementia, but their effectiveness for mild cognitive impairment is unclear. We conducted a systematic review to examine the efficacy and safety of cognitive enhancers for mild cognitive impairment. Our
Yuan-Sheng Zou et al.
Fitoterapia, 136, 104186-104186 (2019-06-01)
Five new amide alkaloids, named delamide A-E (1-5), along with five known ones, methyl-N-(3-carboxy-2-methylpropanoyl) anthranilate (6), benzoic acid, 2-[(1-oxodecyl) amino]-methylester (7), puberline (8), benzoic acid, 2-[(4-methoxy-2-methyl-1, 4-dioxobutyl) amino]-methylester (9) and benzoic acid, 2-[(4-methoxy-3-methyl-1, 4-dioxobutyl) amino]-methylester (10) were isolated from the
2, 4-Disubstituted quinazolines as amyloid-β aggregation inhibitors with dual cholinesterase inhibition and antioxidant properties: Development and structure-activity relationship (SAR) studies.
Mohamed T and Rao PPN
European Journal of Medicinal Chemistry, 126, 823-843 (2017)
Page 1 of 2